Table 2.
Clinical characteristics of CHB-related GBS.
| Virological markers | |||||||||
| Reference | Country or region | Age/sex | Duration of GBS onset from CHB | Symptoms | HBsAg | HBeAg | HBeAb | HBcAb | HBV-DNA |
| Tsukada et al (1987)[6] | Japan | 34/M | 12 yr | Mo/Se/CP | + | − | + | + | NM |
| Japan | 48/F | NM | Mo/Se | + | NM | NM | NM | NM | |
| Han et al (1999)[7] | Taiwan | 46/M | NM | Mo/Se | + | + | + | IgM (−) | NM |
| Taiwan | 29/M | 3 yr | Se | + | − | + | NM | + | |
| Chroni et al (2003)[8] | Greece | 65/M | Ep 1: NM | Mo/Se/CP/RF | + | − | + | IgM (−), IgG (+) | 2235∗ |
| Ep 2: 4 yr | Mo/Se | NM | NM | NM | IgM (+) | 4∗ | |||
| Sonavane et al (2018)[4] | India | 59/M | NM | Mo/CP | + | − | + | IgM (+) | 100,890† |
| Our case 2021 | Chinese mainland | 34/M | 2 yr | Mo/Se/MA/RF | + | − | + | IgM 1:502 | 110,000† |
| CSF | |||||||
| ALT/AST (IU/L) | Total bilirubin (mg/dL) | Ganglioside antibody | Protein level (mg/dL) | WBC count (×106/L) | NCS | Treatment | Prognosis |
| 65/NM | NM | NM | 225 | NM | AIDP | Steroid | Complete recovery |
| 66/52 | NM | NM | 108 | NM | AIDP | Steroid | Complete recovery |
| 1366/750 | NM | NM | 92 | 0 | AIDP | IVIG/PP | Marked recovery |
| 761/383 | 1.7 | NM | 60 | 1 | ASN | IFN-α | Complete recovery |
| 154/125 | 0.9 | NM | 125 | 0 | AIDP | MV/prednisolone/PP/IVIG | Complete recovery |
| 308/156 | 1.2 | NM | 70 | 0 | AIDP | Lamivudine/IVIG | Complete recovery |
| 1345/910 | 14.6 | NM | 247 | 10 | AIDP | Entecavir/IVIG | Complete recovery |
| 231/204 | 5.0 | GD1a, GQ1b, GM1 and GM2 (-) | 72 | 2 | AMSAN&AIDP | TDF/IVIG/MV/hepatoprotection/acupuncture and rehabilitation | Partial recovery |